Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.24.0.1
Commitments and Contingencies (Details Narrative)
€ in Millions
 1 Months Ended 3 Months Ended
Apr. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2023
EUR (€)
Apr. 30, 2023
USD ($)
Jan. 31, 2019
USD ($)
Jul. 31, 2012
USD ($)
Discovery Collaboration Agreements [Member] | XOMA [Member]                  
Loss Contingencies [Line Items]                  
Milestone payments                 $ 3,800,000
Discovery Collaboration Agreements [Member] | XOMA [Member] | In Process Research and Development [Member]                  
Loss Contingencies [Line Items]                  
License fee $ 500,000                
License fees       $ 0 $ 0        
Cellca Agreement [Member]                  
Loss Contingencies [Line Items]                  
Description of milestone payments       The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised.          
Cellca Agreement [Member] | Maximum [Member]                  
Loss Contingencies [Line Items]                  
Milestone payments               $ 700,000  
The Cellca Agreement [Member]                  
Loss Contingencies [Line Items]                  
Milestone payments       $ 600,000          
The Cellca Agreement [Member] | Maximum [Member]                  
Loss Contingencies [Line Items]                  
Payment for annual license fee obligation       600,000          
The Cellca Agreement [Member] | Minimum [Member]                  
Loss Contingencies [Line Items]                  
Payment for annual license fee obligation       100,000          
The Cellca Agreement [Member] | In Process Research and Development [Member]                  
Loss Contingencies [Line Items]                  
License fees $ 100,000     0 0        
The Brink Agreement [Member]                  
Loss Contingencies [Line Items]                  
Payment of annual license fee             $ 12,000    
Commercial product license fee payment obligation       100,000          
The Brink Agreement [Member] | In Process Research and Development [Member]                  
Loss Contingencies [Line Items]                  
License fee       12,000          
License fees         0        
Development license fee payments       100,000          
InvivoGen Agreement [Member]                  
Loss Contingencies [Line Items]                  
License fees       0 0        
Payment for annual license fee obligation       100,000   € 0.1      
ProteoNic Agreement [Member]                  
Loss Contingencies [Line Items]                  
Milestone payments       1,300,000   € 1.2      
License fees       0 0        
ProteoNic Agreement [Member] | In Process Research and Development [Member]                  
Loss Contingencies [Line Items]                  
License fees   $ 24,600              
Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member]                  
Loss Contingencies [Line Items]                  
Milestone payments       1,000,000.0          
Payment to acquire in process research and development     $ 100,000            
Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member] | Research and Development Expense [Member]                  
Loss Contingencies [Line Items]                  
License fees       $ 0 $ 100,000